<DOC>
	<DOCNO>NCT01031784</DOCNO>
	<brief_summary>The HEPAR study aim determine safety radioactive holmium contain microspheres treatment tumor liver . These microspheres administer infusion liver artery use arterial catheter femoral artery .</brief_summary>
	<brief_title>Radioactive Holmium Microspheres Treatment Liver Metastases</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<criteria>Patients meet follow criterion may enter study : 1 . Patients must give write informed consent . 2 . Female male age 18 year . 3 . Confirmed histological diagnosis metastatic malignancy dominant liver metastasis without standard therapeutic option treatment include chemotherapy surgery . Dominant liver metastasis define ( accord Response Evaluation Criteria Solid Tumors ( RECIST ) methodology , see Appendix IV ) diameter metastasis liver must 200 % sum diameter soft tissue lesion outside liver . 4 . Life expectancy 12 week longer . 5 . World Health Organisation ( WHO ) Performance status 02 ( see Appendix III ) . 6 . One measurable lesion least 10 mm long diameter spiral Computed Tomography ( CT ) scan ( 5 mm slice thickness ) accord RECIST criterion . 7 . Negative pregnancy test woman childbearing potential . Patients meet follow criterion enter study : 1 . Brain metastasis spinal cord compression , unless irradiate least 4 week prior date experimental treatment stable without steroid treatment least 1 week . 2 . Radiation therapy within last 4 week start study therapy . 3 . The last dose prior chemotherapy receive less 4 week prior start study therapy . 4 . Major surgery within 4 week , incompletely heal surgical incision start study therapy . 5 . Any unresolved toxicity great National Cancer Institute ( NCI ) , Common Terminology Criteria Adverse Events ( CTCAE version 3.0 , see Appendix II ) grade 2 previous anticancer therapy . 6 . Serum bilirubin &gt; 1.5 x Upper Limit Normal ( ULN ) . 7 . Serum creatinine &gt; 185 µmol/L . 8 . Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase ( ALP ) &gt; 5 x ULN . 9 . Leukocytes &lt; 4.0 109/l and/or platelet count &lt; 150 109/l . 10 . Significant cardiac event ( e.g . myocardial infarction , superior vena cava ( SVC ) syndrome , New York Heart Association ( NYHA ) classification heart disease ≥2 within 3 month entry , presence cardiac disease opinion Investigator increase risk ventricular arrhythmia . 11 . Pregnancy breast feeding ( woman childbearing potential ) . 12 . Comorbidity grave prognosis ( estimate survival &lt; 3 month ) and/or bad basic disease patient include study . 13 . Patients abnormality bile duct ( stent ) increase chance infection bile duct . 14 . Patients suffer disease increase chance liver toxicity , primary biliary cirrhosis xeroderma pigmentosum . 15 . Patients suffer psychic disorder make comprehensive judgement impossible , psychosis , hallucination and/or depression . 16 . Patients declare incompetent . 17 . Previous enrolment present study previous treatment radioembolisation . 18 . Treated investigational agent within 42 day prior start study treatment . 19 . Female patient use acceptable method contraception ( oral contraceptive , barrier method , approve contraceptive implant , longterm injectable contraception , intrauterine device tubal ligation ) OR le 1 year postmenopausal surgically sterile participation study ( time sign consent form ) prevent pregnancy . 20 . Male patient surgically sterile use acceptable method contraception participation study ( time sign consent form ) prevent pregnancy partner . 21 . Evidence portal hypertension , splenomegaly ascites . 22 . Body weight 150 kg . 23 . Active hepatitis ( B and/or C ) . 24 . Liver weight &gt; 3 kg ( determine software use CT data ) . 25 . Allergy i.v . contrast use ( Visipaque® ) . 26 . MRI contraindication : severe claustrophobia , metal shrapnel , implant pacemaker and/or neurostimulators .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>liver metastasis</keyword>
	<keyword>Liver tumor</keyword>
	<keyword>microspheres</keyword>
	<keyword>holmium</keyword>
	<keyword>toxicity</keyword>
</DOC>